	US 12,479,909 B2
	Albumin binding antibodies and use thereof
Ziyang Zhong, Belmont, CA (US); Fan Ye, Mountain View, CA (US); Matthew Siegel, Menlo Park, CA (US); Jianing Huang, San Mateo, CA (US); Eric Liao, San Francisco, CA (US); and Ella Li, San Francisco, CA (US)
Assigned to ANWITA BIOSCIENCES, INC., San Carlos, CA (US)
Appl. No. 17/432,488
Filed by Anwita Biosciences, Inc., San Carlos, CA (US)
PCT Filed Feb. 21, 2020, PCT No. PCT/US2020/019215 § 371(c)(1), (2) Date Aug. 20, 2021, PCT Pub. No. WO2020/172528, PCT Pub. Date Aug. 27, 2020.
Claims priority of provisional application 62/809,475, filed on Feb. 22, 2019.
Prior Publication US 2022/0195021 A1, Jun. 23, 2022
Int. Cl. C07K 16/18 (2006.01); C07K 14/76 (2006.01)

CPC C07K 16/18 (2013.01) [C07K 14/76 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/569 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01)]

30 Claims

1. An isolated anti-albumin construct comprising a single-domain antibody (sdAb) moiety that comprises a heavy chain variable domain having the amino acid sequence of any one of SEQ ID NOs: 45 to 47 and 49 to 53; wherein the anti-albumin construct binds to an albumin.